Authors
Latest:
Accelerating New Medicines: Innovation and Technology at CuriaCuria is proud to partner with pharma and biotech companies to make new medicines that save lives. In order to be able to do that, Curia needs to be constantly innovating. In this podcast, you will learn from Curia’s VP of Portfolio and Sourcing, James Grabowski, about Curia’s small and large molecules most recent technologies, and capabilities.
Latest:
Beyond the Data: Is Blockchain the Answer to Improving Global Health?The COVID-19 pandemic has shifted the adoption of digital platforms in pharma and has made the industry reconsider which technologies can improve global health moving forward.
Latest:
How to Overcome Inertia and Adopt Omnichannel Marketing for PharmaOmnichannel marketing touts delivering efforts across all channels simultaneously, and looks to dethrone the incumbent multichannel marketing, but making the switch isn't exactly easy.
Latest:
Reimagining Medical Education for the Digital AgeEmbracing new digital-based tools is critical throughout the healthcare landscape to prepare for the rise of telemedicine as a permanent way of life.
Latest:
Bottom of the Funnel Conversion though EHR Marketing and its Role in an Omnichannel StrategyWebinar Date/Time: Wed, Dec 7, 2022 2:00 PM EST
Latest:
Challenges to Navigating the Pharmaceutical Regulatory LandscapeIn the United States, the biomedical industry encounters numerous regulatory challenges in conducting nonclinical and clinical studies and managing chemistry, manufacturing, and controls (CMC) activities.
Latest:
If Content Is King, Context Is the Power Behind the ThroneNew mediums of technology must be utilized correctly to reap full benefits.
Latest:
The Real Cost of State Drug Importation Programs? Patient SafetyImporting drugs from Canada may increase the risk of US citizens being exposed to unsafe medicines.
Latest:
Integrating Payers Into Your Digital Communication PlanAn evolving system requires a focus on digital channels
Latest:
Payers Believe Lowering Drug Prices While Improving Patient Access Is Possible—but There’s a CatchValue-based price for access (VBPA) may increase access of specialty drugs for patients.
Latest:
Pharma’s Cold Calling: CGT Space at a Critical CrossroadsAs the overall industry pipeline of allogeneic T-cell therapies expands, the onus on manufacturers and their partners to adeptly manage the complex cryogenic logistics process intensifies.
Latest:
Opening Digital Doors: Remote Selling During COVID-19Adoption of digital by biopharma reps has added an element of flexibility to their engagement strategies, resulting in better communications with HCPs.
Latest:
How False Starts Continue to Undermine Omnichannel EffortsOmnichannel marketing bridges the gap from marketing operations to sales excellence. A well-planned, omnichannel marketing strategy allows pharma companies to reach the right people, at the right time, with the right message. Omnichannel marketing provides a holistic view of the customer to improve stakeholder experience across all touchpoints.
Latest:
Addressing the Knowledge Gap in Biologics & Biosimilars: Is a Board Certified Biologics and Biosimilars Program the Answer?Life sciences professionals will need to keep up with market demand for biologics and biosimilars.
Latest:
Strategic Market Access Ensures the Right Treatments at the Right TimeA robust market access strategy ensures that pharmaceutical products, including those with limited distribution, reach patients and are covered by diverse healthcare systems.
Latest:
Bringing Biotech Innovation Across BordersFour tips for midsized companies when entering new global markets.
Latest:
Breaking OrbitHow pharmaceutical leaders at established companies can still disrupt the status quo and change the game.
Latest:
The Impact of Accelerated Drug DevelopmentDr. Manuel Hermosilla shares his thoughts on how the pharmaceutical industry reacts to challenges that arise during trials, specifically during the search for an effective COVID-19 vaccine.
Latest:
What the Leaders of the Most Effective Teams KnowFindings from hundreds of interviews of exceptional pharma leaders around the world.
Latest:
Ask a Better Question, Make a Better Decision.Harnessing the power of curiosity to position your next big idea
Latest:
The Hardest Job in Biopharma? The Vice President of Market AccessMarket access is about aligning internal strategies with external realities that often change without warning and at a frequency likely not experienced by other biopharma executive roles.
Latest:
Uncovering the Potential of Advanced Analytics in International Price ManagementHow can pharmaceutical companies successfully apply advanced analytics? Pricing experts from Simon-Kucher & Partners identify the hurdles and winning approaches.
Latest:
China 2021 National Reimbursement Drug List OutlookThe 2021 National Reimbursement Drug List (NRDL) process has been unfolding in China since June this year, with several key themes emerging. Building on Simon-Kucher’s experience with the NRDL, the authors make three recommendations on negotiation strategies going into the process.
Latest:
Clues on Equity Engagement LevelsA survey of 18 biopharmas, measuring their scope and implementation across key health equity dimensions and activities, uncovers useful context as companies seek better alignment of these goals with overall strategy.
Latest:
Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial SuccessThe high-stakes nature of cancer care, coupled with rapid scientific advancements and increasing payer and regulatory pressures, demands a specialized approach beyond traditional market access strategies.
Latest:
Payers Believe Lowering Drug Prices While Improving Patient Access Is Possible—but There’s a CatchValue-based price for access (VBPA) may increase access of specialty drugs for patients.
Latest:
AI in Pharma: Where, When, and How Executives are Considering itAs skepticism surrounding AI fades, pharma industry execs are ready to embrace the technology.
Latest:
Manage Risk Effectively to Improve the Value of Your AllianceIn this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.
